Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.09 | -$0.08 | -$0.08 |
Q2 2024 | 1 | -$0.08 | -$0.07 | -$0.08 |
Q3 2024 | 1 | $0.02 | $0.02 | $0.02 |
Q4 2024 | 3 | -$0.03 | $0.06 | $0.03 |
Q1 2025 | 2 | -$0.48 | $0.91 | $0.21 |
Q2 2025 | 1 | $0.18 | $0.21 | $0.19 |
Q3 2025 | 1 | $0.16 | $0.18 | $0.17 |
Q4 2025 | 1 | $0.19 | $0.21 | $0.20 |
Q1 2026 | 1 | $0.35 | $0.39 | $0.37 |
Q2 2026 | 1 | $0.39 | $0.43 | $0.41 |
Q3 2026 | 1 | $0.17 | $0.19 | $0.18 |
Q4 2026 | 1 | $0.11 | $0.13 | $0.12 |
Kiniksa Pharmaceuticals, Ltd. last posted its earnings results on Tuesday, October 29th, 2024. The company reported $-0.18 earnings per share for the quarter, missing analysts' consensus estimates of $-0.02361 by $0.15639. The company had revenue of 112.21 M for the quarter and had revenue of 270.26 M for the year. Kiniksa Pharmaceuticals, Ltd. has generated $0 earnings per share over the last year ($0.2 diluted earnings per share) and currently has a price-to-earnings ratio of -158.28. Kiniksa Pharmaceuticals, Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/29/2024 | Q3 2024 | -$0.02 | -$0.18 | -0.16 | $111.51 M | $112.21 M |
07/25/2024 | Q2 2024 | -$0.06 | $90.60 M | $108.63 M | ||
04/25/2024 | Q1 2024 | -$0.25 | $79.86 M | |||
02/28/2024 | Q4 2023 | -$0.11 | $0.36 | 0.47 | $83.40 M | |
11/02/2023 | Q3 2023 | -$0.20 | $64.55 M | $67.05 M | ||
08/01/2023 | Q2 2023 | $0.21 | $52.06 M | $71.47 M | ||
05/04/2023 | Q1 2023 | -$0.18 | $48.35 M | |||
03/02/2023 | Q4 2022 | $0.06 | $61.88 M | |||
11/03/2022 | Q3 2022 | $3.23 | $93.58 M | $99.14 M | ||
08/04/2022 | Q2 2022 | -$0.29 | $28.42 M | $26.97 M | ||
05/05/2022 | Q1 2022 | -$0.36 | $32.19 M | |||
02/24/2022 | Q4 2021 | -$0.53 | $18.75 M | |||
11/04/2021 | Q3 2021 | -$0.44 | $10.26 M | $12.10 M | ||
08/05/2021 | Q2 2021 | -$0.61 | $4.29 M | $7.70 M | ||
05/06/2021 | Q1 2021 | -$0.72 | $0 | |||
02/25/2021 | Q4 2020 | -$0.79 | $0 | |||
11/05/2020 | Q3 2020 | -$0.59 | -$0.66 | -0.07 | $0 | |
08/04/2020 | Q2 2020 | -$0.65 | $0 | |||
05/04/2020 | Q1 2020 | -$0.48 | $0 | |||
03/05/2020 | Q4 2019 | -$0.58 | $0 |
Kiniksa Pharmaceuticals, Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
The conference call for Kiniksa Pharmaceuticals, Ltd.'s latest earnings report can be listened to online.
The conference call transcript for Kiniksa Pharmaceuticals, Ltd.'s latest earnings report can be read online.
Kiniksa Pharmaceuticals, Ltd. (:KNSA) has a recorded annual revenue of $270.26 M.
Kiniksa Pharmaceuticals, Ltd. (:KNSA) has a recorded net income of $270.26 M. Kiniksa Pharmaceuticals, Ltd. has generated $0.2 earnings per share over the last four quarters.
Kiniksa Pharmaceuticals, Ltd. (:KNSA) has a price-to-earnings ratio of -158.28 and price/earnings-to-growth ratio is -7.91.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED